Generic placeholder image

Inflammation & Allergy - Drug Targets (Discontinued)

Editor-in-Chief

ISSN (Print): 1871-5281
ISSN (Online): 2212-4055

ADAM8 in Allergy

Author(s): Osamu Matsuno, Toshihide Kumamoto and Yasunori Higuchi

Volume 7, Issue 2, 2008

Page: [108 - 112] Pages: 5

DOI: 10.2174/187152808785107598

Price: $65

Abstract

ADAM (a disintegrin and metalloprotease) family members are membrane-anchored proteins with wide ranging functions, including proteolytic cleavage of cell surface molecules, cell fusion, cell adhesion and intracellular signaling. ADAM8, also known as CD156a, is expressed mainly in cells of the immune system, such as monocytes, neutrophils, eosinophils, dendritic cells, and B cells. It can cleave a variety of substrates and is a sheddase for CD23 and L-selectin. ADAM8 has an important role in allergic inflammation. ADAM8 mRNA expression is increased with disease progression in asthma. ADAM8 is strongly induced by allergens and Th2 cytokines in the lung in experimental asthma. Soluble ADAM8 is elevated in the bronchoalveolar lavage fluid of patients with eosinophilic pneumonia and has a physiologic role in protecting against allergic pulmonary disease in experimental murine asthma. Together, these findings support the view that ADAM8 might be a therapeutic target for allergic respiratory diseases. This review discusses novel strategies for immune intervention in allergic respiratory disease.

Keywords: ADAM8, inflammation, allergy, asthma, eosinophilic pneumonia

Next »

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy